Intramembranous bone tissue response to biodegradable octacalcium phosphate implant.
Previous studies showed that synthetic octacalcium phosphate (OCP) enhances bone formation coupled with its own osteoclastic biodegradation more than non-biodegradable hydroxyapatite (HA), including sintered HA ceramic, when implanted in animal bone defects. The present study was designed to investigate whether synthetic OCP in granule form has biodegradable characteristics when implanted in the subperiosteal area of mouse calvaria in comparison with non-sintered stoichiometric HA, especially in relatively short periods after implantation. OCP crystals exhibited plate-like morphology, whereas HA crystals had a sphere-like structure. Both crystals had large pore volumes >75% in total, with micropores within the granules. Direct bonding of newly formed bone was discernible in HA until 35 days after implantation by element analysis for calcium and phosphorus. However, histomorphometric analysis demonstrated that bone formation was facilitated on OCP surfaces with greater alkaline phosphatase activity than on HA up to 21 days. The surfaces attacked by tartrate-resistant acid phosphatase positive osteoclast-like cells were significantly greater than those of HA. OCP became encapsulated and replaced with new bone with prolonged implantation periods up to 180 days. The results suggest that the enhanced bone formation in mouse calvaria could be associated with the biodegradable nature of OCP, and that OCP could be used in augmenting intramembranous bone volume.
Kikawa
T
T
Division of Orthopedic Surgery, Kikawa Hospital, 17 Shimo-cho, Tamachi, Kakunodate-machi, Senboku 014-0312, Japan.
Kashimoto
O
O
Imaizumi
H
H
Kokubun
S
S
Suzuki
O
O
D020341:Absorbable Implants; D000135:Acid Phosphatase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001842:Bone and Bones / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure; D002113:Calcification, Physiologic / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002130:Calcium Phosphates / Q000494:pharmacology*; D017886:Durapatite; D007527:Isoenzymes / Q000378:metabolism; D008566:Membranes / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008855:Microscopy, Electron, Scanning; D010012:Osteogenesis / Q000187:drug effects; D010758:Phosphorus / Q000378:metabolism; D000071681:Tartrate-Resistant Acid Phosphatase; D014961:X-Ray Diffraction
D002130:Calcium Phosphates; D007527:Isoenzymes; C022045:octacalcium phosphate; D010758:Phosphorus; D017886:Durapatite; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D002118:Calcium